Autologous CD34+ hematopoietic stem and progenitor cells with augmented mitochondrial content (MAT-HSPCs)

Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) with augmented mitochondrial content or function represent a novel therapeutic approach for treating primary mitochondrial diseases, such as Pearson Syndrome. In this modality, a patient's own HSPCs are harvested and enriched ex vivo with healthy, functional mitochondria—a process known as Mitochondrial Augmentation Therapy (MAT) (Yivgi-Ohana et al., 2021). The goal is to restore metabolic capacity and oxidative phosphorylation in cells that are otherwise deficient due to large-scale mitochondrial DNA (mtDNA) deletions or mutations (Jacoby et al., 2022). Once re-infused, these augmented stem cells engraft in the bone marrow and differentiate into various blood cell lineages, carrying the healthy mitochondria throughout the hematopoietic system (ClinicalTrials.gov, NCT03384420). This approach aims to alleviate the severe cytopenias and organ failures associated with systemic mitochondrial dysfunction. Clinical development, notably by companies like Minovia Therapeutics, focuses on using maternal donor mitochondria to enhance the energetic profile of the patient's autologous cells (Minovia Therapeutics). The therapy represents a significant shift toward direct organelle transplantation to correct metabolic defects at the cellular level.

Other names

Mitochondrial Augmentation TherapyMATMNV-BM-BLDMitochondria-augmented CD34+ cellsAutologous CD34+ HSPCs - mitochondrial content/function

Mitochondrial Augmentation Therapy (MAT) involves the ex vivo enrichment of autologous CD34+ hematopoietic stem and progenitor cells with healthy, functional mitochondria to restore oxidative phosphorylation and cellular energy production in patients with mitochondrial DNA deletions (Jacoby et al., 2022; Minovia Therapeutics).